Future Market Insights
Search Reports

Hemostatic Gels Market

Starting at US$ 5000

Buy Now
Companies
Industry Size (2025)
USD 1.13 Bn
Forecast (2035)
USD 2.17 Bn
CAGR (2025 to 2035)
6.6%

Hemostatic Gels Market Size, Market Forecast and Outlook By FMI

The hemostatic gels market is expected to expand from USD 1.2 billion in 2026 to USD 2.3 billion by 2036. The market is anticipated to register a 6.6% CAGR during the forecast period. Bovine-based gels are likely to lead with a 38.4% share, and general surgery is projected to account for 41.7% of indication demand in 2026.

Summary of the Hemostatic Gels Market

  • Demand and Growth Drivers
    • Rising surgical volumes are expected to increase the use of gel-based hemostats across operating rooms and critical care units.
    • Trauma care needs are likely to raise demand for fast-acting bleeding control products across emergency and surgical settings.
    • Minimally invasive procedures are anticipated to increase interest in gels suitable for precise application on irregular tissue surfaces.
  • Product and Segment View
    • Bovine-based gels are expected to lead the material segment through strong clotting action and broad procedural acceptance
    • General surgery is likely to account for the leading indication share as abdominal and trauma procedures require rapid bleeding control.
    • Polymer-based gels are anticipated to gain attention as hospitals compare clinical handling benefits.
  • Geography and Competitive Outlook
    • North America is expected to stay a leading regional market through advanced surgical infrastructure and early product adoption.
    • China is likely to record strong expansion as hospital construction and surgical capacity increase across major healthcare systems.
    • Companies with stronger clinical validation and product usability are anticipated to gain preference across hospitals and ambulatory centers.
  • Analyst Opinion
    • Sabyasachi Ghosh, Principal Consultant for Healthcare at FMI, suggests, “The hemostatic gels market is likely to advance through products offering faster bleeding control and easier surgical handling. Manufacturers with proven gel performance across general surgery and cardiovascular procedures are expected to gain stronger acceptance among hospital buyers.”
  • Hemostatic Gels Market Value Analysis
    • The hemostatic gels market is moving into a more procedure-linked healthcare supply segment as surgical volumes increase.
    • Demand is likely to rise as hospitals prioritize products able to reduce blood loss and procedure delays.
    • Adoption is expected to improve as surgeons seek gel formats suitable for moist and irregular anatomical surfaces.
    • Spending is anticipated to strengthen as trauma care systems and advanced surgical workflows expand across major countries.

Key Industry Attributes

Attribute Detail
Industry Size (2026) USD 1.2 billion
Industry Size (2036) USD 2.3 billion
CAGR (2026 to 2036) 6.6%

Analyzing Hemostatic Gels Market by Top Investment Segments

Bovine-based gels lead the market with a 38.4% share, while general surgery dominates with 41.7%, driven by increased surgical procedures and the rising need for effective intraoperative bleeding control. Demand is also influenced by improved biocompatibility and ease of use in diverse clinical settings.

Bovine-Based Hemostatic Gels Dominate with High Efficacy and Clinical Compatibility

Bovine-based hemostatic gels are projected to lead the global market, accounting for 38.4% share in 2025. These gels are favored for their strong coagulative action, biocompatibility, and rapid absorption-making them highly effective in managing surgical bleeding across multiple specialties. Derived from bovine-derived collagen or gelatin, they interact with platelets and fibrin to form a stable clot quickly, reducing operative time and improving patient outcomes.

Their widespread use is attributed to ease of handling, low immunogenic response, and ability to conform to irregular wound surfaces. Bovine-based gels are approved for a broad range of procedures, including general, cardiovascular, orthopedic, and dental surgeries.

Leading manufacturers like Pfizer, Baxter International, and CryoLife have developed advanced bovine-based gel formulations that offer faster resorption, improved hemostasis time, and lower risk of infection. As minimally invasive and robotic-assisted surgeries rise globally, the adaptability and reliability of bovine-derived hemostatic agents will continue to make them the go-to material in operating rooms across hospitals, clinics, and ambulatory surgical centers.

General Surgery Emerges as Key Application with High Volume and Hemostasis Demands

General surgery is anticipated to dominate the hemostatic gels market by application, holding a 41.7% share in 2025. The high prevalence of abdominal, gastrointestinal, and trauma-related procedures drives demand for fast-acting and easy-to-apply hemostatic solutions. Hemostatic gels are increasingly used to manage intraoperative bleeding, particularly in soft tissue procedures where traditional suturing or cauterization is not ideal.

These gels improve surgical efficiency by reducing blood loss, minimizing the need for transfusions, and shortening recovery times. Their effectiveness in both open and laparoscopic surgeries enhances their value in general surgical settings. The shift toward enhanced recovery protocols and same-day discharge models also boosts the adoption of hemostatic gels that ensure immediate and reliable clotting.

Surgeons prefer gels for their precision, minimal residue, and ability to maintain hemostasis even in moist or mobile surgical fields. Companies like Ethicon, B. Braun, and Medtronic are introducing next-gen hemostatic gels tailored for general surgery with improved adhesive properties and antimicrobial enhancements. As surgical volumes continue to rise globally-particularly in aging populations-the demand for hemostatic agents in general surgery will remain robust.

Key Opportunities for Hemostatic Gels Manufacturers

Hemostasis has high clinical importance in preventive, surgical, and emergency circumstances as blood loss may cause substantial diseases and deaths in civil and military individuals owing to bleeding problems rising from surgery, trauma injuries, and as hereditary, disease-related, or drug-induced blood syndromes.

For externally accessible injuries, a range of natural and synthetic biomaterials have to go through strong research, leading to hemostatic technologies including bandages, dressings, fibrin glues, tourniquets, tamponades, and hemostatic powders.

In contrast, treatment of internal non-compressible hemorrhage still severely relies on transfusion of pure blood or blood hemostatic components such as platelets, coagulation factors, and fibrinogens. Transfusion of platelets may experience significant challenges of high cost, limited availability, contamination risks, short shelf-life, performance variability, low portability, and immunological adverse reactions.

The usage of these blood hemostatic components provides only partial mechanisms for hemostasis. Through such concerns, interdisciplinary research is being conducted for the development of hemostatic gels that can be manufactured conveniently, and administered intravenously to mimic, leverage, and amplify physiological hemostatic mechanisms. This is expected to create opportunities for growth in the market for the development of effective and efficient hemostats.

Analysis of Top Countries Using Hemostatic Gels

What is Driving the USA Hemostatic Gels Market?

Increasing Incidence of Lifestyle Related Disorders is Driving Demand for Hemostatic Gels

The USA dominated the North America hemostatic gels market, accounting for 82% of the total markets share in 2024. Rising prevalence of cardiovascular disorders, diabetes, and cancer in the USA. is propelling the volume of surgical procedures, thereby necessitating hemostatic gels.

With the global rise in the incidence of chronic diseases, the volume of surgical procedures is expected to increase in the forthcoming years, which is expected to drive demand hemostatic gels for blood loss management.

According to the CDC, around 150 million Americans are suffering from at least one chronic condition, which leads to the need for surgery. With the growing incidence of chronic diseases, the number of injuries and surgeries is expected to increase, thereby increasing the usage of hemostatic gels in the USA

What is the India Hemostatic Gels Market Outlook?

Rising Expenditure on Healthcare Infrastructure Will Augment Sales of Hemostatic Gels

Demand for hemostatic gels in India is set to increase at a 7.4% CAGR over the assessment period. The market in India is driven by increasing demand for hemostatic gels due to growing government initiatives to create awareness about the product.

For instance, in November 2023, the transport department of the Rajasthan government mandated the addition of feracrylum, a hemostatic gel, in the first aid of all vehicles that are being registered from November 2023 following a direction of the high court. Feracrylum has been recognized to be a hemostatic agent by several clinical studies.

Why the UK Hemostatic Gels Market Considered Lucrative?

Growing Trend of Medical Tourism in the UK Will Fuel the Adoption of Hemostatic Gels

Sales in the UK market are projected to increase at a 7.1% CAGR over the forecast period. As per the British heart foundation (UK) and its heart and circulatory disease statistics, in 2020, there has been a substantial surge in the number of cardiac surgeries such as aortic valve replacement and angioplasty in the UK

Hemostatic gels have higher application in cardiovascular surgeries due to better clinical outcomes compared to other wound closure techniques. Thus, a growing number of cardiac surgeries is expected to spur demand for effective hemostatic gels in the UK

What Makes the China Hemostatic Gels Market Attractive?

Increaisng Establishment of Hospitals and Ambulatory Centers in China Will Propel Demand for Hemostatic Gels

China held approximately 38.0% of the East Asia hemostatic gels market in 2024. As per the report, sales are forecast to grow at a 8.0% CAGR through 2035.

The government in China is investing heavily in the construction of healthcare infrastructure such as hospitals and clinics. As per an article published in 2023, China announced an investment of USD 4.6 Billion for the construction of hospitals in Wuhan.

There are now about 26,000 hospitals in China, more than in any other country; among them 60% are public and 40% are in the private sector. The significant growth in the number of hospitals and surgical centers is expected to boost sales of hemostatic gels.

Competitive Landscape of the Hemostatic Gels Market

Leading players operating in the global hemostatic gels market are launching innovative products to meet the demand for a hemostatic gel that can be easily and specifically applied, particularly for irregular fractures where bandages can be difficult, and powders are messy and can cause uneasiness. For instance:

  • In July 2021, Medcura, Inc., and ASO, LLC collaboratively launched Rapid-Seal, a high-performance, antibacterial hemostatic gel which is available on several e-commerce sites and the shelves at a leading USA drugstore chain.
  • In December 2021, Cresilon, Inc. submitted a 510(k) premarket notification to the USA FDA for its registered hemostatic gel which is followed by the successful launch of Cresilon's VETIGEL, an innovative hemostatic gel for the veterinary use.

With several competitors in hemostatic gels manufacturing, the overall market is highly fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships, and collaborations. For instance:

  • In July 2021, Baxter International Inc. completed the acquisition of CryoLife, Inc. for certain assets related to PerClot, a polysaccharide hemostatic system for USD 60.8 Million.

Scope and Coverage of the Hemostatic Gels Market Report

Report Attributes Details
Market Size (2025) USD 1.13 billion
Projected Market Size (2035) USD 2.17 billion
CAGR (2025 to 2035) 6.6%
Base Year for Estimation 2024
Historical Period 2020 to 2024
Projections Period 2025 to 2035
Quantitative Units USD billion for value and million units for volume
Materials Analyzed (Segment 1) Bovine-Based, Porcine-Based, Polymer-Based
Indications Analyzed (Segment 2) General Surgery, Dental Surgery, Veterinary Surgery, Cardiovascular Surgery, Orthopaedic Surgery, Others
End Users Analyzed (Segment 3) Hospitals, Speciality Clinics, Veterinary Settings, Ambulatory Surgical Centers, Online Sales
Regions Covered North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa
Countries Covered United States, Canada, Brazil, Mexico, Germany, France, United Kingdom, Italy, China, Japan, South Korea, India, Australia, UAE, Saudi Arabia, South Africa
Key Players Influencing the Market Baxter, Bio to Chem LLC, Clinician's Choice Dental Products Inc., Cresilon (VETIGEL), DSI Ltd., ENDOVISION CO., LTD, Ethicon USA LLC, F&A Medical, PrevestDenPro, Septodont, Teleflex Incorporated, Ultradent Products Inc., VladMiVa, Medcura Inc.
Additional Attributes Manufacturers of hemostatic gels market would want to know dollar sales by material type, share by surgery category and end user, demand surge in dental and general surgery, price competitiveness, and usage trends in ambulatory vs. hospital settings.

Top Segments Studied in the Hemostatic Gels Market Research Report

By Material:

  • Bovine-Based
  • Porcine-Based
  • Polymer-Based

By Indication:

  • General Surgery
  • Dental Surgery
  • Veterinary Surgery
  • Cardiovascular Surgery
  • Orthopaedic Surgery
  • Others

By End-User:

  • Hospitals
  • Speciality Clinics
  • Veterinary Settings
  • Ambulatory Surgical Centers
  • Online Sales

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

What is the sales forecast for the hemostatic gels market through 2035?

The hemostatic gels market is expected to reach USD 2.17 billion by the end of 2035, with sales revenue expected to register at 6.6% CAGR.

What are the key trends shaping the hemostatic gels industry?

The growing volume of surgical procedures and the increasing need for hemostatic gels in blood loss management are some of the key trends in this market.

Which are the top 5 countries driving demand for hemostatic gels?

The USA the UK, India, China, and Brazil are expected to drive demand for the hemostatic gels industry.

What is the North American market outlook for hemostatic gels?

North America is one of the key markets for hemostatic gels, with the USA accounting for about 82% of the North American hemostatic gels market in the year 2024.

At what percentage is the demand for hemostatic gels expected to register growth in Europe?

Demand for hemostatic gels in Europe is expected to register a growth of 7.1% over the next ten years.

Which countries are the key producers of hemostatic gels?

The USA, the UK, India, and China are the key producers of hemostatic gels.

Who are the key players in the hemostatic gels market sphere?

Baxter, Bio-Chem LLC, Clinician's Choice Dental Products Inc., Cresilon, Inc., Dsi Ltd., Endovision Co., Ltd, Ethicon USA, LLC, F&A Medical, Prevestdenpro, Septodont, Teleflex Incorporated, Ultradent Products Inc. All, Vladmiva And Medcura, Inc., Are Some Of The Key Players In The Hemostatic Gels Industry.

Preview the report firsthand - request a free sample

Get Sample

Get the brochure for pricing and purchase details.

Future Market Insights

Hemostatic Gels Market